Radharani Gollamudi, MD
Internal Medicine · Indianapolis, INNPI 1245287713
Payments from drug & device makers
Across 64 payments — averaging $33.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$480
- Otsuka America Pharmaceutical, Inc.$479
- Neurocrine Biosciences, Inc.$236
- Astellas Pharma US Inc$186
- Acadia Pharmaceuticals Inc$158
- Sumitomo Pharma America, Inc.$139
- plus $462 from 9 others
What the payments were for
- Food & beverage$1,98593%
- Education$1557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 32 | $480 |
| Otsuka America Pharmaceutical, Inc. | 5 | $479 |
| Neurocrine Biosciences, Inc. | 2 | $236 |
| Astellas Pharma US Inc | 8 | $186 |
| Acadia Pharmaceuticals Inc | 4 | $158 |
| Sumitomo Pharma America, Inc. | 2 | $139 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Neurelis, Inc. | 1 | $101 |
| AstraZeneca | 1 | $100 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Novartis | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $17 |
| Cipher Pharmaceuticals US LLC | 1 | $17 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,141 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,527 | $465,379 |
| NuplazidPimavanserin Tartrate | 73 | $177,809 |
| SantylCollagenase Clostridium Hist. | 70 | $74,023 |
| GemtesaVibegron | 252 | $72,058 |
| JanuviaSitagliptin Phosphate | 188 | $57,830 |
| TrulicityDulaglutide | 81 | $46,158 |
| Invega SustennaPaliperidone Palmitate | 12 | $44,160 |
| LinzessLinaclotide | 76 | $43,929 |
| XareltoRivaroxaban | 134 | $41,578 |
| NuedextaDextromethorphan Hbr/Quinidine | 80 | $39,434 |
| EntrestoSacubitril/Valsartan | 116 | $38,459 |
| RybelsusSemaglutide | 37 | $37,937 |
| MyrbetriqMirabegron | 148 | $36,702 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 236 | $31,588 |
| Memantine Hcl | 536 | $26,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $158 | $177,80973 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto, Procrit | $12 | $112,004161 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $139 | $72,058252 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $49 | $39,43480 claims |
| NovartisEntresto | $25 | $38,459116 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $36,702148 claims |
| AstraZenecaFarxiga | $100 | $25,53686 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $479 | $17,00618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Indianapolis
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- Georgiann LinnemeierIndianapolis$692K
- Allon FriedmanIndianapolis$524K
- Eromonsele IdahosaIndianapolis$471K
- Misty ShieldsIndianapolis$411K
- Pei LuIndianapolis$298K
- Paul DexterIndianapolis$161K
- Jon DukeIndianapolis$138K
- Napoleon MamintaIndianapolis$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.